CA2286408A1 - The use of msm - Google Patents
The use of msm Download PDFInfo
- Publication number
- CA2286408A1 CA2286408A1 CA 2286408 CA2286408A CA2286408A1 CA 2286408 A1 CA2286408 A1 CA 2286408A1 CA 2286408 CA2286408 CA 2286408 CA 2286408 A CA2286408 A CA 2286408A CA 2286408 A1 CA2286408 A1 CA 2286408A1
- Authority
- CA
- Canada
- Prior art keywords
- lotions
- creams
- msm
- preparations
- skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Preparations containing methylsulfonylmethane (MSM) for administration to the skin, nails, other tissue and/or body fluids of a human or other animal subject.
These include cosmetics and toiletries for skin care, hair care, body care and complete lines of colour cosmetics. Hair care products, namely shampoo, conditioner, rinse preparations, styling gel, hair spray, skin care products, namely cleansing preparations, liquid foam bath, shower gel, moisturizing creams and lotions, suntan creams, oils and lotions, massage lotions, shaving creams, hand creams and lotions, bar and liquid soaps. In addition, preperations with MSM for use orally, by injection or by inhalation, tableting and a granulating (powder) aid.
These include cosmetics and toiletries for skin care, hair care, body care and complete lines of colour cosmetics. Hair care products, namely shampoo, conditioner, rinse preparations, styling gel, hair spray, skin care products, namely cleansing preparations, liquid foam bath, shower gel, moisturizing creams and lotions, suntan creams, oils and lotions, massage lotions, shaving creams, hand creams and lotions, bar and liquid soaps. In addition, preperations with MSM for use orally, by injection or by inhalation, tableting and a granulating (powder) aid.
Description
Methylsulfonylmethane is effective in maintaining good health and in improving poor health of animals, including human beings and is a source of dietetic sulfur.
Applied topically, such compositions soften skin, strengthen nails and provide other benefits. For topical administration, MSM compositions may be formulated in creams, lotions or gels which may be used alone or to serve as stable, neutral vehicles for other skin conditioning substances or therapeutically active drugs. Aqueous MSM
solutions are suitable blood diluents. MSM compositions may also be administered orally, by injection or by inhalation.
In many instances, the effectiveness of MSM compositions is enhanced when such compositions contain carbamide (urea) Methylsulfonylmethane (CH(3) SO(2) CH(3)) administered orally is effective in ameliorating the symptoms of gastrointestinal upset, e.g., produced by the ingestion of aspirin and other pharmaceuticals, and of allergic reactions. Oral compositions containing a mixture of such a pharmaceutical and methylsulfonylmethane are useful in avoiding the gastrointestinal upset which otherwise occurs when ingesting the former.
Methylsulfonylmethane (MSM) is useful as a tableting and granulating aid for pharmaceutically active agents, especially those which are unstable in the presence of moisture, mixtures therewith being or formable into free-flowing powders or granules which are readily compressible into tablets of improved properties. A
preferred method of forming such powders or granules involves mixing the pharmaceutically active agent under substantially anhydrous conditions with molten MSM or with particulate solid MSM at its softening point, cooling the resultant mixture and, when the MSM
was molten, forming the solidified melt into granules or a free flowing powder and thereafter, if desired, compressing the powder or granules into tablets.
Methylsulfonylmethane is effective in treating parasitic infections in animals including human beings.
Use of methylsulfonylmethane to relieve pain and nocturnal cramps and to reduce stress-induced deaths in animals.
MSM also aids rn management of snoring.
A method of pharmaceutically managing snoring is provided by the instillation intra-nasally of a solution containing 1-20% methylsulfonylmethane by weight dissolved in water so as to saturate the nasal mucous membranes. Preferably, the solution has between 10%-16% by weight methysulfonylmethane. The solution may be buffered, and/or a mild analgesic may be included. The method prefers that instillation occur as close to the event as possible, and it should be at least within one hour before a person retires for sleep. The solution may be introduced by spray or drop-wise.
For additional information please go to http://www.bulkmsm.com/Default.html.
~~ rs't ~~~ ~ seG~ : S c~'~" $,1q 9 9 r Colin Russell #29 Greenwood Village Sherwood Park, Alberta Canada, T8A 018 ~~;, >~~ f l
Applied topically, such compositions soften skin, strengthen nails and provide other benefits. For topical administration, MSM compositions may be formulated in creams, lotions or gels which may be used alone or to serve as stable, neutral vehicles for other skin conditioning substances or therapeutically active drugs. Aqueous MSM
solutions are suitable blood diluents. MSM compositions may also be administered orally, by injection or by inhalation.
In many instances, the effectiveness of MSM compositions is enhanced when such compositions contain carbamide (urea) Methylsulfonylmethane (CH(3) SO(2) CH(3)) administered orally is effective in ameliorating the symptoms of gastrointestinal upset, e.g., produced by the ingestion of aspirin and other pharmaceuticals, and of allergic reactions. Oral compositions containing a mixture of such a pharmaceutical and methylsulfonylmethane are useful in avoiding the gastrointestinal upset which otherwise occurs when ingesting the former.
Methylsulfonylmethane (MSM) is useful as a tableting and granulating aid for pharmaceutically active agents, especially those which are unstable in the presence of moisture, mixtures therewith being or formable into free-flowing powders or granules which are readily compressible into tablets of improved properties. A
preferred method of forming such powders or granules involves mixing the pharmaceutically active agent under substantially anhydrous conditions with molten MSM or with particulate solid MSM at its softening point, cooling the resultant mixture and, when the MSM
was molten, forming the solidified melt into granules or a free flowing powder and thereafter, if desired, compressing the powder or granules into tablets.
Methylsulfonylmethane is effective in treating parasitic infections in animals including human beings.
Use of methylsulfonylmethane to relieve pain and nocturnal cramps and to reduce stress-induced deaths in animals.
MSM also aids rn management of snoring.
A method of pharmaceutically managing snoring is provided by the instillation intra-nasally of a solution containing 1-20% methylsulfonylmethane by weight dissolved in water so as to saturate the nasal mucous membranes. Preferably, the solution has between 10%-16% by weight methysulfonylmethane. The solution may be buffered, and/or a mild analgesic may be included. The method prefers that instillation occur as close to the event as possible, and it should be at least within one hour before a person retires for sleep. The solution may be introduced by spray or drop-wise.
For additional information please go to http://www.bulkmsm.com/Default.html.
~~ rs't ~~~ ~ seG~ : S c~'~" $,1q 9 9 r Colin Russell #29 Greenwood Village Sherwood Park, Alberta Canada, T8A 018 ~~;, >~~ f l
Claims
Preparations containing methylsulfonylmethane (MSM) for administration to the skin, nails, other tissue and/or body fluids of a human or other animal subject.
These include cosmetics and toiletries for skin care, hair care, body care and complete lines of colour cosmetics. Hair care products, namely shampoo, conditioner, rinse preparations, styling gel, hair spray, skin care products, namely cleansing preparations, liquid foam bath, shower gel, moisturizing creams and lotions, suntan creams, oils and lotions, massage lotions, shaving creams, hand creams and lotions, bar and liquid soaps. tn addition, preperations with MSM for use orally, by injection or by inhalation, tableting and a granulating (powder) aid.
These include cosmetics and toiletries for skin care, hair care, body care and complete lines of colour cosmetics. Hair care products, namely shampoo, conditioner, rinse preparations, styling gel, hair spray, skin care products, namely cleansing preparations, liquid foam bath, shower gel, moisturizing creams and lotions, suntan creams, oils and lotions, massage lotions, shaving creams, hand creams and lotions, bar and liquid soaps. tn addition, preperations with MSM for use orally, by injection or by inhalation, tableting and a granulating (powder) aid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA 2286408 CA2286408A1 (en) | 1999-09-15 | 1999-09-15 | The use of msm |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA 2286408 CA2286408A1 (en) | 1999-09-15 | 1999-09-15 | The use of msm |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2286408A1 true CA2286408A1 (en) | 2001-03-15 |
Family
ID=4164384
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA 2286408 Abandoned CA2286408A1 (en) | 1999-09-15 | 1999-09-15 | The use of msm |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA2286408A1 (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1294368A1 (en) * | 2000-06-02 | 2003-03-26 | Elstan Corporation | Management of snoring by oral administration of dimethyl sulfone |
| US8182794B2 (en) * | 2003-03-05 | 2012-05-22 | Concept Laboratories | Sunless tanning products and processes |
| FR3066392A1 (en) * | 2017-05-16 | 2018-11-23 | Neo Lupus | COMPOSITION BASED ON PLANT COMPONENTS FOR TREATING OR TREATING SKIN AND / OR HAIR IN ANIMALS |
| US10980791B1 (en) | 2018-01-26 | 2021-04-20 | Gene S. Rosen | Multi-component nutritional supplement formulations and treatment regimen |
| US11369558B1 (en) | 2018-01-26 | 2022-06-28 | Gene S. Rosen | Multi-component nutritional supplement formulations and treatment regimen |
-
1999
- 1999-09-15 CA CA 2286408 patent/CA2286408A1/en not_active Abandoned
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1294368A1 (en) * | 2000-06-02 | 2003-03-26 | Elstan Corporation | Management of snoring by oral administration of dimethyl sulfone |
| EP1294368A4 (en) * | 2000-06-02 | 2006-04-12 | Elstan Corp | Management of snoring by oral administration of dimethyl sulfone |
| US8182794B2 (en) * | 2003-03-05 | 2012-05-22 | Concept Laboratories | Sunless tanning products and processes |
| FR3066392A1 (en) * | 2017-05-16 | 2018-11-23 | Neo Lupus | COMPOSITION BASED ON PLANT COMPONENTS FOR TREATING OR TREATING SKIN AND / OR HAIR IN ANIMALS |
| US10980791B1 (en) | 2018-01-26 | 2021-04-20 | Gene S. Rosen | Multi-component nutritional supplement formulations and treatment regimen |
| US11369558B1 (en) | 2018-01-26 | 2022-06-28 | Gene S. Rosen | Multi-component nutritional supplement formulations and treatment regimen |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5898037A (en) | Formulations of magnesium compounds for local application and methods of treatment using the same | |
| EP1888024B1 (en) | Topical compositions | |
| KR100924476B1 (en) | Topical glycopyrrolate product | |
| US3549770A (en) | Therapeutic administration of effective amounts of dimethyl sulfoxide to human and animal subjects | |
| Lin et al. | Salicylic acid revisited. | |
| MXPA97005954A (en) | Formulations and methods to reduce irritation of the p | |
| HU218936B (en) | Topical pharmaceutical composition containing anorganic salt of stroncium (ii) for treating skin irritation | |
| JP2012511515A (en) | Compositions and methods for topical application | |
| JPH10513452A (en) | Formulations and methods for reducing skin irritation | |
| JP2015096506A (en) | Compositions for prophylaxis and treatment of dermatological/mucosal diseases, and uses thereof | |
| JP2004500353A5 (en) | ||
| US4369190A (en) | Analgesic composition and use thereof to ameliorate intractable pain | |
| WO2011119247A2 (en) | Topical skincare composition | |
| JP2004501939A5 (en) | ||
| CA2286408A1 (en) | The use of msm | |
| US20160101139A1 (en) | Topical treatment for use as a sleep aid | |
| US3629412A (en) | Topical anti-inflammatory agent | |
| US6399108B1 (en) | Compositions and methods for the treatment of skin disorders | |
| US20040204492A1 (en) | Topical composition and method for treating seborrheic dermatitis | |
| Lockhart et al. | Hexachlorophene decisions at the FDA | |
| CA2512942A1 (en) | An improved method of treating inflammatory acne vulgaris and rosacea with carbamide peroxide | |
| KR930001301B1 (en) | Pharmaceutical composition for skin disease | |
| Pike | Cocaine withdrawal: An effective three-drug regimen | |
| JP2003119157A (en) | Mouth wash preparation containing collagen | |
| Dhaon et al. | Efficacy and Safety of Nimesulide Transdermal Gel versus Diclofenac and Piroxicarn Gel in Patients with Acute Musculoskeletal Condition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Dead |